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SUMMARY
Rhinogenic headache is frequently encountered in clinical practice. Treatment of this condition should be based on a proper evaluation of 
its underlying pathophysiology. Fixed-dose combinations of two or more active agents, and specifically the combination of ibuprofen plus 
pseudoephedrine, have been shown to be more efficacious than either monotherapy. At present, an ibuprofen/pseudoephedrine fixed-dose 
combination is available as an over-the-counter drug. This paper reviews in detail the pathophysiology of rhinogenic headache and dis-
cusses the rationale for treatment of this condition with a fixed-dose ibuprofen/pseudoephedrine combination.
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RIASSUNTO 
La cefalea rinogena è frequente nella pratica clinica. Il trattamento di questa patologia dovrebbe essere basato su un’appropriata valuta-
zione della sottostante fisiopatologia. La combinazione di due o più farmaci, ed in particolare ibuprofene e pseudoefedrina, a dosaggi fissi 
si è dimostrata più efficace delle monoterapie. Al momento la combinazione ibuprofene/pseudoefedrina a dosaggio fisso è commercializza-
ta quale farmaco da banco. Questo lavoro si focalizza sulla revisione in dettaglio della fisiopatologia della cefalea rinogenica e discute il 
razionale del trattamento mediante la combinazione ibuprofene/pseudoefedrina.
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Introduction
Rhinogenic headache represents a major health issue that 
is frequently encountered in clinical practice 1. The results 
of a worldwide survey in 2007 showed that rhinogenic 
headache is among the most common complaints among 
those seeking medical care. In addition to general practi-
tioners, otolaryngologists see a large number of patients 
with rhinogenic headache 2. Most patients with this condi-
tion are males aged 10-30 years 2-5.
Rhinogenic headaches have their primary pathophysiol-
ogy centred in the nose, with headache and/or facial pain 
as a result of complex neurohumoral reflexes. The most 
common rhinogenic headache is that associated with 
acute rhinosinusitis  4  6. Most cases of rhinogenic head-
ache are caused by viral infections (up to 98%), and only 
2% are complicated by bacterial sinusitis  1  7. However, 
primary care physicians often treat sinusitis as an acute 
bacterial infection, prescribing antibiotic therapy and 
hence contributing to the onset of resistance 1. In addition, 
rhinogenic headache is frequently misdiagnosed as other 
conditions such as migraine 2.
Therefore, it is important to identify and appropriately 
manage this common condition  1. Treatment should be 
based on a proper evaluation of the underlying patho-
physiology. Fixed-dose combinations of two or more ac-
tive agents, and specifically the combination of ibuprofen 
plus pseudoephedrine, have been shown to be more effica-
cious than either monotherapy. At present, an ibuprofen/
pseudoephedrine fixed-dose combination is available as 
an over-the-counter product 8. 
This paper reviews in detail the pathophysiology of rhi-
nogenic headache and discusses the rationale for treat-
ment of this condition with a fixed-dose ibuprofen/pseu-
doephedrine combination.
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Pathophysiology and clinical features  
of rhinogenic headache
The paranasal sinuses are lined with pseudostratified co-
lumnar epithelium, and under physiological conditions, 
the sinuses are normally sterile. Their function depends 
on regular transport of the mucus layer into a common ar-
ea, the osteomeatal complex, in the middle meatus of the 
nasal cavity. This area is the focal point of sinus drainage; 
from the nasal cavity, the mucus then drains into the oro-
pharynx 1. Acute rhinosinusitis begins as a viral infection 
of the nose leading to inflammation of the sinuses. Inflam-
mation leads to mucosal oedema, osteomeatal complex 
obstruction and development of negative atmospheric 
pressure within the sinuses cavities and decreasing partial 
pressure of oxygen. Excessive mucus production, with or 
without transudation of plasma, also occurs. Collectively, 
these events result in malfunction or complete cessation 
of movement of the cilia in the sinuses, leading to stasis 
of the mucus. Inevitably, this creates an environment that 
promotes the growth of pathogenic organisms 1. In addi-
tion, specific anatomic variations, smoking, immunodefi-
ciency disease, allergic rhinitis and exposure to increasing 
levels of humidity or irritants promote decreased ciliary 
function, sinus obstruction and superinfection 1 9.
Mucosal inflammation represents the central pathophysi-
ological mechanism underlying most of the specific and 
interrelated factors that contribute to congestion, such as 
increased venous engorgement, increased nasal secretions 
and tissue swelling/oedema  10. Inflammation diminishes 
the physical size of the nasal passages by inducing va-
sodilatation and increasing blood flow as well as vascular 
permeability. The result is engorgement of the nasal ve-
nous sinusoids, swelling of the anterior and inferior tur-
binates and obstruction of nasal airflow. Ultimately, this 
engorgement leads to nasal congestion 10.
Given the contribution of inflammation, it is not surpris-
ing that the levels of inflammatory cytokines (interleukin 
(IL)-1, IL-6, IL-8, tumour necrosis factor (TNF)-α) in pa-
tients with acute rhinosinusitis are significantly increased 
in nasal lavage fluid compared with healthy controls 10-12. 
Kinin levels are markedly increased in nasal secretions 
of patients with acute viral rhinosinusitis: these polypep-
tides act on blood vessels to cause vascular leakage and/
or engorgement, and also stimulate afferent nerve fibres 
leading to hyperresponsiveness of the mucosa 13 14. In ad-
dition, acute rhinosinusitis is associated with increased 
infiltration of inflammatory cells, including neutrophils 
and T cells, in the nasal epithelium and lamina propria 10.
Sterile inflammation (so-called neurogenic inflamma-
tion) may result from neurologic responses involving a 
wide range of neurotransmitter systems  10. In particular, 
the nasal mucosa has sensory, parasympathetic and sym-
pathetic nerves. Sensation to the nasal cavity is provided 
primarily via the maxillary and ophthalmic branches of 
the trigeminal nerve. Parasympathetic innervation controls 
nasal secretions and mucus gland production; moreover, it 
increases blood flow to the nasal cavity by release of NO. 
On the other hand, sympathetic innervation decreases the 
blood flow to the nasal cavity and nasal mucosa. In the 
presence of mucosal inflammation, parasympathetic and 
sympathetic tone is dysfunctional, and therefore changes 
in both glandular and vascular function in the nose occur.
The hypothesis of polymodal receptors in the nasal mucosa 
suggests that different heat, chemical and mechanical ir-
ritants (such as pressure on the mucosa) may cause antidro-
mic release of neuropeptides including substance P and cal-
citonin gene-related peptide 15 from the peripheral terminals 
of nociceptive sensory nerve fibres 10, as well as vasoactive 
neuro-gasotransmitters (noradrenalin, acetylcholine, NO, 
adenosine) involving sympathetic and parasympathetic ter-
minals. This leads to neurogenic inflammation and periph-
eral neural sensitisation, which bring about a complex cas-
cade of neurohumoral signalling that is mainly sustained 
by reflex mechanisms 10. Specifically, the perivascular re-
lease of the above-mentioned powerful vasodilators causes 
increased vessel permeability, plasma extravasation and 
tissue oedema, which further activate afferent trigeminal 
sensory fibres and, in turn, continuous antidromic release 
of vasoactive and inflammatory molecules. Inevitably, this 
leads to a vicious cycle of neurogenic inflammation that 
sustains rhinorrhoea, nasal congestion, sinus pain and up-
per respiratory symptoms 6 10 16. With regard to rhinogenic 
headache, it is now known that this originates both by clas-
sic mechanisms of painful stimuli converging at the level 
of the trigeminal nucleus (the trigeminocervical complex) 
and activation of the parasympathetic loop, which plays 
a crucial role not only in sustaining mucosa vasodilation 
but also in intracranial spreading of neurogenic inflamma-
tion. Specifically, painful stimuli reaching the trigeminal 
nucleus activate direct signalling to the superior saliva-
tory nucleus, which sends preganglionic parasympathetic 
fibres to the sphenopalatine ganglion. Postganglionic fibres 
close the reflex arch by sending fibres traveling together 
with the trigeminal fibres and innervating not only the na-
sal and sinus mucosa but also intracranial structures, such 
as the meninges and pial vessel. Hence, parasympathetic 
activation caused by sustained nasal mucosa inflammation 
triggers perivascular release of vasodilating compounds at 
the meninges and cerebral vessels, which activates and then 
sensitizes the terminals of trigeminal nociceptors with de-
velopment of rhinogenic headache 17 18.
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Rhinogenic headache and facial pain develop simultane-
ously with the onset or exacerbation of rhinosinusitis and 
usually resolve after remission or successful treatment of 
acute rhinosinusitis 2. Sudden onset of two or more symp-
toms, including nasal discharge/rhinorrhoea, nasal block-
age or congestion, facial pain/pressure/frontal headache 
and disorder of olfaction, of less than 10 days duration, 
is considered to be caused by a virus (common cold) 1 9. 
Treatment should be initiated immediately for patients 
with rhinogenic headache 2.
Treatment optimisation for rhinogenic 
headache
Given the particular pathophysiology of rhinogenic head-
ache, optimal therapy should induce prompt resolution of 
oedema/mucosa compression, suppression of inflamma-
tion, safe analgesia and stimulation of the central nervous 
system (CNS) within specific hypothalamic and brain-
stem nuclei to restore neurovegetative homeostasis 1.
Current treatments for rhinogenic headache include de-
congestants, anticholinergics, anti-histamine, corticoster-
oids, analgesics and anti-bacterial agents 1. The different 
therapies used in this setting are sustained by different lev-
els of evidence. Given that each of the above-mentioned 
drugs acts only against a subset of symptoms, fixed-dose 
combinations of two or more active ingredients are fre-
quently used in clinical practice 19.
Analgesics, and especially ibuprofen, have a major role in 
the treatment of rhinogenic headache 16. In this regard, it is 
worth remembering that the updated guidelines (2015) of 
the AAO-HNS (American Academy of Otorhinolaryngol-
ogy - Head and Neck Surgery) for treatment of acute rhi-
nosinusitis give a recommendation to analgesic for relief 
of both viral and bacterial ARS (Acute RhinoSinusitis) 
symptoms 20.
The main mechanism of action of ibuprofen is non-se-
lective, reversible inhibition of cyclooxygenase enzymes 
COX-1 and COX-2. COX-1 and COX-2 catalyse the first 
step in the synthesis of proinflammatory prostanoids from 
arachidonic acid. These prostanoids enhance oedema 
formation, increase vascular permeability and promote 
leukocyte infiltration; they also reduce the threshold of 
nociceptor sensory neurons to stimulation. Ibuprofen ex-
erts its anti-inflammatory and analgesic effects mostly by 
inhibiting the formation of these prostanoids 21. Moreover, 
ibuprofen has inhibitory effects on polymorphonuclear 
leukocyte migration and function 22 23. It also inhibits the 
release and biological effects of kinins and inflammatory 
mediators such as TNF-α and IL1, which are involved in 
the recruitment of neutrophils, thus exerting an immu-
noregulatory effect  24. In addition, ibuprofen is reported 
to scavenge reactive oxygen and nitrogen species and to 
inhibit NO synthesis 21.
Ibuprofen has an excellent safety/tolerability profile even 
after multiple doses; the frequency of gastrointestinal ad-
verse events is comparable with placebo  25. In patients 
with cold and flu symptoms enrolled in a large study 
(n = 2815), ibuprofen was as well tolerated as paraceta-
mol and much better tolerated than aspirin 26. In a clinical 
trial on 80 patients with naturally acquired upper respira-
tory tract infections, ibuprofen 400 mg three times daily 
significantly reduced the severity of headache-associated 
symptoms, earache, muscle/joint pain, and sneezing, and 
also reduced body temperature 27.
Oral decongestants are another commonly used class of 
medications for the treatment of rhinogenic headache 1. 
They are prescribed usually on a short-term basis to pro-
vide fast-acting relief. Oral decongestants have a weaker 
effect on nasal obstruction than topical intranasal de-
congestants; however, they do not cause a rebound phe-
nomenon. After oral administration, the effect of nasal 
decongestion occurs within 30 minutes and persists for 
up to 6 hours. Decongestants contain sympathomimet-
ic agents, which mimic the actions of norepinephrine. 
Pseudoephedrine mainly exerts its vasoconstrictive ef-
fects by promoting noradrenaline release, thereby behav-
ing as an indirect vasoconstrictor. It has indirect agonist 
activity, particularly on peripheral α1 and cardiac β re-
ceptors through displacement of noradrenaline from the 
vesicle pool. Displaced norepinephrine is then released 
from the sympathetic prejunctional nerve terminal and 
subsequently binds to post-junctional α-adrenergic re-
ceptors on nasal venous sinusoids, thereby producing 
vasoconstriction, plasma extravasation and mucosal 
congestion 28.
Pseudoephedrine at the low dose used in over-the-coun-
ter medicines may cause nasal decongestion with mini-
mal cardiac effects  29. Small, but statistically significant 
increases in pulse and systolic blood pressure occurred 
after supramaximal doses of pseudoephedrine (120  mg 
and 180  mg). Conversely, pseudoephedrine at 60  mg is 
the optimal, single adult dose leading to prompt, maxi-
mal nasal decongestion without cardiovascular or other 
unwanted effects 30.
Role of the fixed-dose combination  
of ibuprofen and pseudoephedrine  
in clinical practice
According to the available evidence, a fixed-dose combi-
nation of ibuprofen and pseudoephedrine may be particu-
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larly effective in the treatment of rhinogenic headache 31. 
It combines two molecules with complementary mecha-
nisms of action, namely reduction of pain and inflamma-
tion with ibuprofen and decrease of nasal oedema, mu-
cous production and congestion with pseudoephedrine. 
Moreover, pseudoephedrine reduces compression on 
nociceptive terminals, thus boosting the analgesic effects 
of ibuprofen. Lastly, pseudoephedrine can help restore 
neurovegetative homeostasis. Indeed, by enhancing the 
sympathetic tone, it counteracts hyperactivation of the 
parasympathetic component that sustains vasodilation 
and neurogenic inflammation.
The clinical evidence supports effective management of 
the nasal and paranasal congestion syndrome with the 
ibuprofen/pseudoephedrine combination. Specifically, in 
a randomised study, 58 patients were assigned to receive 
pseudoephedrine 60  mg alone, pseudoephedrine 60  mg 
plus ibuprofen 200 mg, or placebo, four times daily for 
4.5 days beginning 30  h after intranasal inoculation of 
rhinovirus under double-blind conditions 31. The frequen-
cies of infection, colds and viral shedding did not dif-
fer significantly between groups. Total symptom scores 
were significantly reduced by 59% by pseudoephedrine 
plus ibuprofen and 48% by pseudoephedrine alone, com-
pared with placebo. Cumulative nasal scores and systemic 
scores were significantly reduced in patients receiving 
pseudoephedrine plus ibuprofen compared with those as-
signed to placebo, whereas pseudoephedrine alone was 
not better than placebo in reducing nasal congestion. 
Combination therapy was well tolerated, with an inci-
dence of adverse events comparable to placebo (Table I).
In a recent study, data from an anonymous survey among 
1770 pharmacy customers purchasing a product contain-
ing 200  mg ibuprofen plus 30  mg pseudoephedrine for 
treatment of common cold symptoms were reviewed  8. 
Scores of symptoms responsive to ibuprofen (headache, 
pharyngeal pain, joint pain and fever), responsive to pseu-
doephedrine (congested nose, congested sinus and runny 
nose), and considered non-specific (sneezing, fatigue, dry 
cough, cough with expectoration) were analysed. After the 
first intake, the greatest improvement in a specific symp-
tom (+ 63% vs baseline) was reported for headache, which 
was also the most bothersome symptom. Nasal and sinus 
congestion improved by more than 50% (Table II). More 
than 50% of participants reported symptom relief within 
30 min (Fig. 1). The duration of overall symptom relief was 
reported to be up to 6 h in 54.4% and up to 12 h in 22.6% 
of patients. Statistical analysis showed that two tablets for 
the first dose were more effective than one. More than 95% 
of participants rated global tolerability as excellent or good.
Conclusions
Rhinogenic headache is frequently encountered in clinical 
practice. Given the particular pathophysiology of this con-
dition, optimal therapy should target multiple pathogenic 
events and lead to resolution of oedema/mucosa compres-
sion and inflammation, as well as promote analgesia and 
CNS stimulation within specific hypothalamic and brain-
stem nuclei to restore neurovegetative homeostasis.
Table I. Adverse events with the ibuprofen/pseudoephedrine combination. Pseudoephedrine only and placebo, as reported by Sperber et al. 31.
Number (percent) of patients
Number of 
patients
Any adverse 
event
Light-
headedness
Difficulty 
Sleeping
Lethargy Indigestion Other
Pseudoephedrine plus ibuprofen 23 6 (26) 2 (9)* 1 (4)§ 0 0 4 (17)§^
Pseudoephedrine alone 23 4 (17) 2 (9)* 0 1 (4) 1 (4) 0
Placebo 10 2 (20) 0 1 (10) 1 (10) 0 0
* Sum of all pseudoephedrine recipients (4/46) was not significantly different from placebo (0/10); § One patient reported difficulty sleeping and dry mouth; ^ One patient 
reported dry mouth, feeling hyper, feeling more awake, flushed face and increased heart rate. Increased pulse rate was not documented in this patient.
Table II. Scores for typical ibuprofen-responsive symptoms at baseline and after intake of the first dose of the combination 200 mg ibuprofen plus 30 mg 
pseudoefedrine (irrespective of taking 1 or 2 tablets) as well as intra-individual change after firts intake.
Score Baseline After first intake Reduction % Reduction
TIRS 4.62 ± 2.19 1.87 ± 1.69 2.75 ± 1.89 60.0 ± 33.2
TPRS 4.89± 2.33 2.50 ± 1.74 2.39 ± 1.93 46.3 ± 64.6
NSS 3.33 ± 2.03 1.81 ±1.58 1.52 ± 1.53 45.4 ± 41.0
TSS 4.22 ± 1.65 2.02 ± 1.42 2.20 ± 1.41 52.8 ± 29.7
TIRS, typical ibuprofen-responsive symptoms consisting of headache, pharyngeal pain, joint pain and fever; TPRS, typical pseudoephedrine-responsive symptoms consisting 
of congested nose, congested sinus and runny nose; NSS, non-specific-symptoms consisting of sneezing, fatigue, dry cough, cough with expectoration; TSS < total symptoms 
consisting of all 11 symptoms. Data are means ± SD on a scale of 0 (smallest extent) to 10 (greatest extent) or % change (reproduced from Klimek et al., 2017 8).
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Due to their mechanism of action, ibuprofen and pseu-
doephedrine may represent a suitable therapeutic strat-
egy for the treatment of rhinogenic headache. In par-
ticular, ibuprofen reduces pain and inflammation, and 
pseudoephedrine contributes to decrease nasal oedema, 
congestion and neurovegetative dysregulation. Although 
current clinical evidence is still limited, the effects of the 
combination are significant with regard to clinical and 
safety/tolerability aspects. The fixed-dose combination 
of ibuprofen and pseudoephedrine has potential to have 
a major role in clinical practice for the management of 
rhinogenic headache.
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